Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
However, in a large study involving people with diabetes who had no comorbidities, GLP-1 RAs were not shown to increase the risk of developing pancreatitis at any time point up through 5 years of use.[ref][ref][ref][ref] The Cleveland Clinic now counsels that GLP-1 RA patients should be screened for pancreatitis risk factors, and a lower dose should be used to reduce the risk of pancreatitis.[ref] Related article : Pancreatitis and Genetic Risk Factors Gastroparesis: Case reports tie semaglutide to a risk of gastroparesis (very slow stomach emptying)
Bottom Line Its hard to know whats truly in the patches, what those ingredients do when theyre absorbed by the skin and what risks consumers may be taking by using them, White warns
GLP-1 RAs enhance or mimic the same functions in the body
What approach do you recommend dermatologists take with patients who are either currently on or are considering using GLP-1 agonists
Biochem Pharmacol 2023;213:115613.ArticlePubMedPMC 36
[1] Dulaglutide (Trulicity): 0.75 mg or 1.5 mg once weekly for type 2 diabetes
,aspect=fit)
